GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avanos Medical Inc (NYSE:AVNS) » Definitions » Return-on-Tangible-Equity

Avanos Medical (Avanos Medical) Return-on-Tangible-Equity : 21.59% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Avanos Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Avanos Medical's annualized net income for the quarter that ended in Dec. 2023 was $42.0 Mil. Avanos Medical's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $194.6 Mil. Therefore, Avanos Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 21.59%.

The historical rank and industry rank for Avanos Medical's Return-on-Tangible-Equity or its related term are showing as below:

AVNS' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -26.46   Med: 11.67   Max: 39.9
Current: -26.46

During the past 13 years, Avanos Medical's highest Return-on-Tangible-Equity was 39.90%. The lowest was -26.46%. And the median was 11.67%.

AVNS's Return-on-Tangible-Equity is ranked worse than
67.32% of 765 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs AVNS: -26.46

Avanos Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Avanos Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avanos Medical Return-on-Tangible-Equity Chart

Avanos Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.68 -9.44 2.02 16.17 -24.85

Avanos Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.29 -0.76 -113.08 -6.76 21.59

Competitive Comparison of Avanos Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Avanos Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avanos Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Avanos Medical's Return-on-Tangible-Equity falls into.



Avanos Medical Return-on-Tangible-Equity Calculation

Avanos Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-61.8/( (296.7+200.7 )/ 2 )
=-61.8/248.7
=-24.85 %

Avanos Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=42/( (188.4+200.7)/ 2 )
=42/194.55
=21.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Avanos Medical  (NYSE:AVNS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Avanos Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Avanos Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Avanos Medical (Avanos Medical) Business Description

Traded in Other Exchanges
Address
5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. The firm operates in one segment, medical devices, which primarily sells products related to pain management, IV Therapy, and respiratory and digestive health. The company divides its Medical Devices segment into two franchises: Pain Management and Chronic Care. Pain Management provides non-opioid products for acute and interventional pain, including cold and compression therapy. Chronic Care aims at addressing digestive and respiratory issues with feeding tubes and catheters. Avanos generates most of its revenue from its Chronic Care franchise and in North America.
Executives
Sudhakar Varshney officer: SVP, Global Supply Chain 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
John Joseph Hurley officer: Principal Accounting Officer 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Patrick J Oleary director 31515 BALLANTYNE CORP, C/O SPX CORP, CHARLOTTE NC 28277
Mojirade James officer: SVP, General Counsel 5405 WINDWARD PKWY, ALPHARETTA GA 30004
Kerr Holbrook officer: SVP, GM Chronic Care 5405 WINDWARD PKWY, ALPHARETTA GA 30004
Michael Greiner officer: SVP - Chief Financial Officer C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421
David Edward Ball officer: SVP - Global Supply Chain AVANOS MEDICAL, INC., 5405 WINDWARD PKWY, ALPHARETTA GA 30004
William David Haydon officer: SVP, GM Pain Franchise 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Arjun Ranjan Sarker officer: Senior VP, International HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Joseph Fralin Woody director, officer: Chief Executive Officer 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004
Steven E Voskuil officer: See Remarks 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
John W Wesley director 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
John Raymond Tushar officer: President, Global Franchises HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004